In this issue of Cancer Cell, Bosse et al. report GPC2 as a therapeutic target in neuroblastoma. They show that GPC2 is selectively expressed on the cell surface of neuroblastoma and is a dependency in this disease. Moreover, they demonstrate the therapeutic potential of an antibody-drug conjugate targeting GPC2. In this issue of Cancer Cell, Bosse et al. report GPC2 as a therapeutic target in neuroblastoma. They show that GPC2 is selectively expressed on the cell surface of neuroblastoma and is a dependency in this disease. Moreover, they demonstrate the therapeutic potential of an antibody-drug conjugate targeting GPC2.
CITATION STYLE
Malone, C. F., & Stegmaier, K. (2017, September 11). Scratching the Surface of Immunotherapeutic Targets in Neuroblastoma. Cancer Cell. Cell Press. https://doi.org/10.1016/j.ccell.2017.08.011
Mendeley helps you to discover research relevant for your work.